Meta-analysisof effect comparison of Paliperidone Sustained-release Tablets and Aripiprazole in the treatment of schizophrenia
LI Yan1 BA Wen-qiang2 YUAN Ye-feng3▲
1.Department of Psychiatry,Ji′an Third People′s Hospital,Jiangxi Province,Ji′an 343000,China;
2.Department of Pharmacy,Ji′an Central People′s Hospital,Jiangxi Province,Ji′an 343000,China;
3.Department of Psychosomatic Medicine,the First Affiliated Hospital of Nanchang University,Jiangxi Province,Nanchang 330000,China
Abstract：Objective To compare the effect and adverse reactions of Paliperidone Sustained-release Tablets and Aripiprazole in the treatment of schizophrenia by Meta-analysis.Methods Randomized controlled trials(RCTs)related to the Paliperidone Sustained-release Tablets and Aripiprazole in the treatment of patients with schizophrenia were searched in China National Knowledge Infrastructure,Wanfang,Weipu Database,Chinese Biomedical Literature Service System,PubMed,Embase,Cochrane Library databases.Search time was from the establishment of the database to October 2019.Meta-analysis was carried out with RevMan 5.3 software.Results Finally,a total of 22 RCTs literatures were included.Meta-analysis showed that compared with the Aripiprazole group,the reduction of total score of positive and negative symptoms scale (PANSS)in the Paliperidone Sustained-release Tablets group was better after 2 and 4 weeksof treatment,and the differences were statistically significant(after 2 weeks of treatment：MD=-8.43,95%CI[-14.61,-2.26],P=0.007;after 4 weeks of treatment：MD=-5.23,95%CI[-9.57,-0.89],P=0.02).After 8 weeks of treatment,there were no significant differences in the PANSSscore(MD=-5.47,95%CI[-11.31,-0.38],P=0.07),positive symptoms score(MD=-2.49,95%CI[-7.33,2.34],P=0.31),and the general psychotic symptoms score(MD=-1.43,95%CI[-5.99,3.12],P=0.54)between the two groups.Compared with Aripiprazole group,the reduction of negative symptoms score of Paliperidone Sustained-release Tablets group was better,and the difference was statistically significant(MD=-1.18,95%CI[-2.10,-0.26],P=0.01).The prolactin level in the Paliperidone Sustained-release Tablets group was higher than that in the Aripiprazole group,and the difference was statistically significant(MD=31.39,95%CI[13.62,49.15],P=0.0005).There was no significant difference in the incidence of adverse reactions between the two groups of patients(P＞0.05).Conclusion Paliperidone Sustained-release Tablets are as effective as Aripiprazole in the treatment of schizophrenia.However,it has faster onset and much better effect for the negative symptoms.The incidence of adverse reactions between the two drugs is similar,but Paliperidone Sustained-release Tablets can increase the serum prolactin level of patients.
李艳 巴文强 袁也丰. 帕利哌酮缓释片与阿立哌唑治疗精神分裂症效果比较的Meta分析[J]. 中国当代医药, 2020, 27(24): 27-32.
LI Yan1 BA Wen-qiang2 YUAN Ye-feng3▲. Meta-analysisof effect comparison of Paliperidone Sustained-release Tablets and Aripiprazole in the treatment of schizophrenia. 中国当代医药, 2020, 27(24): 27-32.
American Psychiatric Association.DSM-IV-TR：Diagnostic and Statistical Manual of Mental Disorders，4th edn，text revision[J].Washington，DC：American Psychiatric Association，2000：739-799.
[6]
Jadad AR，Moore RA，Carroll D，et al.Assessing the quality of reports of randomized clinical trials：is blinding necessary?[J].Control Clin Trials，1996，17（1）：1-12.
Adam J，Rosanne L，Isaac N，et al.Efficacy and safety of paliperidone extended release in adolescents with schizophrenia：A Randomized，Double-Blind Study[J].JAm Acad Child Adolesc Psychiatry，2015，54（2）：126-137.
[29]
Fowler JA，Bettinger TL，Argo TR.Paliperidone extendedrelease tablets for the acute and maintenance treatment of schizophrenia[J].Clin Ther，2008，30（2）：231-248.
[30]
Zhang JP，Robinson DG，Gallego JA，et al.Association of a schizophrenia risk variant at the DRD2 locus with antipsychotic treatment response in first-episode psychosis[J].Schizophr Bull，2015，41（6）：1248-1255.
[31]
Bartolomeis A，Tomasetti C，Iasevoli F.Update on the mechanism of action of aripiprazole：translational insights into antipsychotic strategies beyond dopamine receptor antagonism[J].CNSDrugs，2015，29（9）：773-799.
[32]
Melnik T，Soares BG，Puga ME，et al.Efficacy and safety of atypical antipsychotic drugs（quetiapine，resperidone，aripiprazole and paliperidone）compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia：overview of systematic reviews[J].Sao Paulo Med J，2010，128（3）：141-166.
[33]
Canuso CM，Youss ef EA，Bossie CA，et al.Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone[J].Int Clin Psychopharmacol，2008，23（4）：209-215.
[34]
Qiao Y，Yang F，Li C，et al.Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone[J].Psychiatry Res，2016，237：83-89.
[35]
Petty RG.Prolactin and antipsychotic medications：mechanism of action[J].Schizophrenia Res，1999，35 Suppl：S67-S73.
京公网安备 11010502046607号